Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group
Authors:
Open Access
- 1 November 2017
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 65 (3)
Abstract
Background: Erwinia asparaginase is a Food and Drug Administration approved agent for the treatment of acute lymphoblastic leukemia (ALL) for patients who develop hypersensitivity to Escherichia coli derived asparaginases. Erwinia asparaginase is efficacious, but has a short half‐life, requiring six doses to replace one dose of the most commonly used first‐line asparaginase, pegaspargase, a polyethylene glycol (PEG) conjugated E. coli asparaginase. Pegcristantaspase, a recombinant PEGylated Erwinia asparaginase with improved pharmacokinetics, was developed for patients with hypersensitivity to pegaspargase. Here, we report a series of patients treated on a pediatric phase 2 trial of pegcrisantaspase.Procedure: Pediatric patients with ALL or lymphoblastic lymphoma and hypersensitivity to pegaspargase enrolled on Children's Oncology Group trial AALL1421 (Jazz 13‐011) and received intravenous pegcrisantaspase. Serum asparaginase activity (SAA) was monitored before and after dosing; immunogenicity assays were performed for antiasparaginase and anti‐PEG antibodies and complement activation was evaluated.Results: Three of the four treated patients experienced hypersensitivity to pegcrisantaspase manifested as clinical hypersensitivity reactions or rapid clearance of SAA. Immunogenicity assays demonstrated the presence of anti‐PEG immunoglobulin G antibodies in all three hypersensitive patients, indicating a PEG‐mediated immune response.Conclusions: This small series of patients, nonetheless, provides data, suggesting preexisting immunogenicity against the PEG moiety of pegaspargase and poses the question as to whether PEGylation may be an effective strategy to optimize Erwinia asparaginase administration. Further study of larger cohorts is needed to determine the incidence of preexisting antibodies against PEG‐mediated hypersensitivity to pegaspargase.Keywords
Funding Information
- National Cancer Institute (CA98543, U10, CA98413, CA180886, CA180899, K12 CA090433-11)
This publication has 38 references indexed in Scilit:
- Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemiaBlood, 2010
- The cross-reactivity of anti-asparaginase antibodies against different l-asparaginase preparationsClinical and Experimental Medicine, 2009
- Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemiaBlood, 2006
- Long-Term Results of a Randomized Trial on Extended Use of High Dose l-Asparaginase for Standard Risk Childhood Acute Lymphoblastic LeukemiaJournal of Clinical Oncology, 2005
- Pharmacokinetic/Pharmacodynamic Relationships of Asparaginase FormulationsClinical Pharmacokinetics, 2005
- Asparaginase Antibody and Asparaginase Activity in Children With Higher-Risk Acute Lymphoblastic LeukemiaJournal of Pediatric Hematology/Oncology, 2004
- A randomized comparison of nativeEscherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group studyBlood, 2002
- Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01Blood, 2001
- Four-Agent Induction and Intensive Asparaginase Therapy for Treatment of Childhood Acute Lymphoblastic LeukemiaNew England Journal of Medicine, 1986
- Antibodies against Polyethylene Glycol Produced in Animals by Immunization with Monomethoxy Polyethylene Glycol Modified ProteinsInternational Archives of Allergy and Immunology, 1983